Palomar Medical (PMTI) wieder über 1 $ - 500 Beiträge pro Seite

[ajuga]

PMTI hat es gestern bei hohem Volumen geschafft, die 1 $ Marke deutlich zu überschreiten. Die Aktie stieg um 36 Prozent oder 36 Cents auf 1,35 $. Grund war die Nachricht, dass PMTI sein EsteLux-Lasersystem in Europa besser vermarkten kann, da es die CE-Designation erhalten hat.

Palomar Receives CE Mark Designation for EsteLux System

7/29/2002 10:30:00 AM
Expands distribution into Europe

BURLINGTON, Mass., Jul 29, 2002 /PRNewswire-FirstCall via COMTEX/ -- Palomar Medical Technologies Inc (PMTI) announced that it has received "CE" certification for its Palomar EsteLux(TM) light-based system. The CE mark is a requirement for products to be sold in the European market. The Palomar EsteLux system received the CE designation after meeting stringent safety and performance standards.

Chief Executive Officer Joseph P. Caruso commented, "The CE designation opens up the tremendous European market for our EsteLux system, which could significantly increase sales of this popular product. Our success in commercializing this light-based hair removal and vascular and pigmented lesion removal device is evident with the ramp up in revenues as reported in the second quarter ended June 30, 2002. This ramp up trend is continuing in the third quarter and we expect the EsteLux system to have the same overwhelming impact in Europe that it has already had here in the U.S., Japan, Australia and other countries. Through July, our performance has exceeded all the milestones set for fiscal 2002. As stated in the second quarter press release and conference call last week, the Company realized a net profit and positive cash flow six months earlier than previously estimated. The outlook for the balance of the year looks very promising."

Caruso continued, "We have a world-class manufacturing facility producing the EsteLux system, and we are expanding our production manpower to increase our monthly capacity even further to meet the strong demand. We have recently signed distributors in Europe and are currently working on expanding European distribution. With the increased production and CE mark in place, allowing us to expand this domestic success into the European market, we look forward to significant international sales boosting our overall revenues."

To get more information regarding Palomar and its products, please visit Palomar`s web site at www.palmed.com. Also, to continue to receive the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the e-mail alerts page in the Investor Relations` section of the web site.


Auch die kürzlich veröffentlich Quartalszahlen geben Grund für Optimismus:

Palomar Medical Reports Second Quarter Results

7/25/2002 8:01:00 AM
Achieves Profitability, Positive Cash Flow and 53 Percent Gross Profit on Increased Revenue

BURLINGTON, Mass., Jul 25, 2002 /PRNewswire-FirstCall via COMTEX/ -- Palomar Medical Technologies Inc (PMTI) said today that for the second quarter ended June 30, 2002, its total revenues increased by 32 percent, its product revenues increased by 58 percent and its gross profit improved by 97 percent as compared to the second quarter of 2001, excluding back-owed royalties of $1.2 million received in the second quarter of 2001. Based on the increased revenues and improved margin, the Company realized a net profit two quarters earlier than management had stated on the April 2002 conference call. Even more importantly, the Company created a positive cash flow with an increase in its cash position over the first quarter ended March 31, 2002. Over the past year, gross margins have improved significantly due to a shift in product mix to lower cost platforms. Chairman of the Board Dan Valente attributed the strong financial performance to the successful execution of the strategic business plan resulting in the Company`s increased market share directly attributable to the recently introduced products.

Revenues for the quarter ended June 30, 2002, were $6.4 million, up from $6.1 million in the second quarter of 2001. Gross profit increased to $3.4 million (53 percent of revenues), up from $2.4 million (40 percent of revenues) in the year-earlier quarter. The Company reported net income of $219,000 or $0.02 per share for the second quarter of this year, versus a net loss of $573,000 or $0.06 loss per share for the second quarter of last year.

Revenues for the six months ended June 30, 2002, were $10.6 million, up from $9.7 million for the six months ended June 30, 2001. Gross profit increased to $5.1 million (48 percent of revenues), up from $3.3 million (35 percent of revenues) in the year-earlier period. The Company reported a net loss of $517,000 or $0.05 per share for the six months ended June 30, 2002, versus a net loss of $2.5 million or $0.25 loss per share for the six months ended June 30, 2001.

Chief Executive Officer Joseph P. Caruso commented, "Achieving profitability is indeed a significant event for Palomar as we accomplished our stated goal of turning the Company around by the end of 2002. We achieved this milestone sooner than expected due to the dedication of our employees and the guidance of our directors, all while investing the necessary resources in Research & Development to maintain our technology leadership position." Caruso continued, "We believe that our EsteLux(TM) Pulsed Light system will continue to penetrate the market based on the favorable reviews of dermatologists and other treatment providers around the world. The EsteLux system has a wide range of applications, including hair removal and vascular and pigmented lesion removal. As expected, we began shipments of the new handpieces for the EsteLux system in this quarter. We offer features that are not available elsewhere, and a tradition of excellent science, design and strong support that is widely trusted. We will continue to build our distribution worldwide."

Conference Call: As previously announced, Palomar will conduct a conference call and webcast today at 11:30 AM EST. Management will discuss second quarter financial results and strategic matters. If you would like to participate, please call [phone] or listen to the webcast in the Investor Relations` section of the Company`s website at www.palmed.com. A webcast replay will also be available for 10 days.

About Palomar Medical Technologies Inc: Palomar is the leading researcher and developer of laser/light based systems for hair removal and other cosmetic treatments and is the first company to obtain clearance from the FDA for "permanent hair reduction." Palomar systems have been installed in practices worldwide, and hundreds of thousands of treatments have been performed. New and exciting indications are being tested to further advance the hair removal market and other cosmetic applications including fat reduction, acne treatment and skin rejuvenation.

For more information on Palomar and its products, visit Palomar`s website at www.palmed.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the E-mail Alerts page in the Investor Relations` section of the website.

[Kurumba]

der wert läuft seit 5 tagen auf 30% hoch - und die zahlen gibts erst ende februar - bin neugierig, ob wir endlich mal die 2 sehen werden

[Kurumba]

hat noch jemand welche - läuft echt gut

[Kurumba]

gehst du etwa auf 3 oder sogar 4$?????????????ß

[Kurumba]

nicht den mut verlieren - da gehts noch mal rauf

[Kurumba]

aufgepasst, da steigen fonds ein - GILLETTE ist ein starker partner

[Kurumba]

tja, die alten werte, die den turnaround geschafft haben...

[Kurumba]

habt ihr gesehen - usa brief 5$ -ist ja wohl übertrieben

[Kurumba]

nicht rausgehen - da gehts noch mal richtig ab - bin ich hier alleinunterhalter oder was???

[trikala]

...ein sehr intertessanter wert

[ErstesRobbenbaby]

Der Chart sieht ja gut aus, aber 38 cent Buchwert/aktie und dafür soll ich über 3$ hinblättern, ich weiß nicht.
Weißt Du etwas über Konkurenten?

[Kurumba]

wieso konkurrenz - doch wohl kaum, wenn gillette 7 mio in diese firma steckt - bei 3$ werden jedenfalls in den us große stücke nachgekauft - allen investierten glück

kurumba

[Kurumba]

danke, TRIKALA, stimmt

[ajuga]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Kurumba]

ist zwar alles möglich - aber ich denke nicht , dass es auf 3$ zurückgeht

[benefactor [KommA]]

[Kurumba]

hier wirds noch weiter steil bergauf gehen - diese firma kommt von 12o $ und hat buisiness und technologie äußerst erfolgreich weiterentwickelt -

[benefactor [KommA]]

Woher die kommen spielt keine Rolle. Aber es sieht wirklich gut aus für PMTI. Die 6$ sollten wir bald sehen.

[Kurumba]

@benefactor - sieht so aus

[benefactor [KommA]]

5,20$

[Kurumba]

1o% von 14% heute gehalten - geht mir alles ein bisschen schnell - andererseits gabs heute good news- weitere FDA zulassung -

[Kurumba]

superaktie

[benefactor [KommA]]

Wir werden die 6$ sehen!

[Kurumba]

bin gespannt, wie es nach den zahlen weitergeht

[Kurumba]

also meinetwegen - steigen wir mit AJUGA bei 3 wieder ein

[Kurumba]

mein KZ 10$

[Kurumba]

ganz schön ärgerlich heute, was?

[Kurumba]

also - falls es hier noch jemanden interessiert - vergesst nicht während eurer asienhype, dass es werte gibt, die in asien geschäfte machen - auch wenn sie in diesem jahr schon 400% gestiegen sind, steigen sie weiter

[Kurumba]

leider sind unsere freunde hysterisch und haben nix aufm konto

[Kurumba]

ich würde jedem raten, hier bei 6,50 euro einzusteigen -

[Kurumba]

na also

[Kurumba]

komisch - das ist ein ruhiges board - keiner sagt was - aber ich halte selbstgepräche

[benefactor [KommA]]

Jetzt haben wir bald die 10$ bei PMTI.